4//SEC Filing
TABUTEAU HERRIOT 4
Accession 0001193125-25-267467
CIK 0001579428other
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 7:01 PM ET
Size
20.1 KB
Accession
0001193125-25-267467
Insider Transaction Report
Form 4
TABUTEAU HERRIOT
DirectorChief Executive Officer10% Owner
Transactions
- Sale
Common Stock
2025-11-03$132.34/sh−91,705$12,136,240→ 7,229 total - Sale
Common Stock
2025-11-04$133.79/sh−50,459$6,750,910→ 7,229 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-05−21,775→ 251,797 totalExercise: $134.49From: 2017-05-27Exp: 2026-05-27→ Common Stock (21,775 underlying) - Exercise/Conversion
Common Stock
2025-11-03$8.02/sh+91,705$735,474→ 98,934 total - Exercise/Conversion
Common Stock
2025-11-04$8.02/sh+50,459$404,681→ 57,688 total - Exercise/Conversion
Common Stock
2025-11-05$8.02/sh+21,775$174,636→ 29,004 total - Sale
Common Stock
2025-11-05$134.49/sh−21,775$2,928,520→ 7,229 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-04−50,459→ 273,572 totalExercise: $133.79From: 2017-05-27Exp: 2026-05-27→ Common Stock (50,459 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-03−91,705→ 324,031 totalExercise: $132.34From: 2017-05-27Exp: 2026-05-27→ Common Stock (91,705 underlying)
Holdings
- 7,344,500(indirect: See Footnote)
Common Stock
Footnotes (7)
- [F1]Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $124.16 and $137.59.
- [F5]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $131.50 and $135.90.
- [F6]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $131.60 and $135.49.
- [F7]Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
Documents
Issuer
Axsome Therapeutics, Inc.
CIK 0001579428
Entity typeother
Related Parties
1- filerCIK 0001219927
Filing Metadata
- Form type
- 4
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 7:01 PM ET
- Size
- 20.1 KB